Nasdaq · CIK 0001681087
TECX Tectonic Therapeutic, Inc.
Insider trading from SEC Form 4. Last filing 11 d ago. Close $23.33 on Oct 9, 2026, +46% from the 52-week low and -38% from the high.
In brief
Tectonic Therapeutic, Inc. (TECX) has 59 SEC Form 4 filings on file from 12 insiders, the latest filed on Oct 2, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 3 open-market sells worth $15k, net -$15k.
16 open-market trades have been scored at TECX. The newest: Peter McNamara (Chief Scientific Officer) sold $12k of stock on Sep 30, 2026, filed Oct 2, 2026, scored 0 (weak), under a 10b5-1 plan. The largest of the 16 shown: Timothy A Springer (director and 10% owner) bought $10M on Oct 22, 2024, scored 43 (moderate). 2 insiders sold within 14 days of each other around Mar 6, 2026.
9 Form 144 notices of planned sales are on file, the latest filed Sep 30, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Tectonic Therapeutic, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Peter McNamara Chief Scientific Officer sell | $12k 536 shares | -1% | +56% from low-39% from high | |
| 0Weak | Peter McNamara Chief Scientific Officer sell | $1,570 43 shares | -0% | +156% from low-1% from high | |
| 0Weak | Peter McNamara Chief Scientific Officer sell | $1,505 43 shares | -0% | +150% from low-3% from high | |
| 0Weak | Peter McNamara Chief Scientific Officer sell | $6,020 172 shares | -0% | +134% from low-4% from high | |
| 0Weak | Marcella K. Ruddy Chief Medical Officer sell | $32k 1,065 shares | -2% | +102% from low-17% from high | |
| 0Weak | Marcella K. Ruddy Chief Medical Officer sell | $31k 1,000 shares | -1% | +110% from low-14% from high | |
| 5Weak | Peter McNamara Chief Scientific Officer sell | $189k 6,262 shares | -10% | +145% from low0% from high | |
| 22Weak | Marcella K. Ruddy Chief Medical Officer sell | $300k 10,000 shares | -13% | +145% from low0% from high | |
| 12Weak | Peter McNamara Chief Scientific Officer sell | $78k 3,299 shares | -8% | +66% from low-8% from high | |
| 48Moderate | Alise Reicin Chief Executive Officer buy | $53k 2,500 shares | +2% | +50% from low-38% from high | |
| 48Moderate | Alise Reicin Chief Executive Officer buy | $53k 2,500 shares | +1% | +50% from low-38% from high | |
| 55Moderate | Daniel Lochner Chief Financial Officer buy | $130k 6,000 shares | +23% | +43% from low-41% from high | |
| 53Moderate | Timothy A Springer director, owner buy | $2.3M 141,923 shares | +3% | +15% from low-69% from high | |
| 61Notable | Timothy A Springer director, owner buy | $8.6M 500,000 shares | +12% | 0% from low-72% from high | |
| 50Moderate | Terrance McGuire director sell | $8.6M 500,000 shares | -47% | 0% from low-72% from high | |
| 43Moderate | Timothy A Springer director, owner buy | $10M 300,000 shares | +8% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 30, 2026 | PETER MCNAMARA Officer | 493 0.00% of outstanding | $12k | Sep 30, 2026 | $3,075 |
| Aug 27, 2026 | TERRANCE MCGUIRE Former Director | 7,513 0.04% of outstanding | $277k | Aug 27, 2026 | $384k |
| Aug 21, 2026 | TERRANCE MCGUIRE Former Director | 10,200 0.05% of outstanding | $384k | Aug 21, 2026 | none |
| Aug 12, 2026 | PETER MCNAMARA Officer | 129 0.00% of outstanding | $4,111 | Aug 12, 2026 | $6,020 |
| Jun 30, 2026 | PETER MCNAMARA Officer | 172 0.00% of outstanding | $5,691 | Jun 30, 2026 | none |
| Mar 6, 2026 | PETER MCNAMARA Officer | 6,262 0.03% of outstanding | $174k | Mar 6, 2026 | $78k |
| Mar 6, 2026 | MARCELLA RUDDY Officer | 12,065 0.06% of outstanding | $336k | Mar 6, 2026 | none |
| Mar 4, 2026 | PETER MCNAMARA Officer | 1,650 0.01% of outstanding | $40k | Mar 4, 2026 | $36k |
| Mar 3, 2026 | PETER MCNAMARA Officer | 1,649 0.01% of outstanding | $38k | Mar 3, 2026 | none |
Transactions
The newest 50 of 97 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Marc Schwabish Chief Business Officer | FTax withholding Common Stock | -411 | $23.67 | $9,728 | 44,903 | 11 d ago |
| Sep 25, 2026 | Alise Reicin Chief Executive Officer | FTax withholding Common Stock | -1,545 | $23.67 | $37k | 309,078 | 11 d ago |
| Sep 25, 2026 | Marcella K. Ruddy Chief Medical Officer | FTax withholding Common Stock | -525 | $23.67 | $12k | 67,157 | 11 d ago |
| Sep 25, 2026 | Daniel Lochner Chief Financial Officer | FTax withholding Common Stock | -520 | $23.67 | $12k | 58,024 | 11 d ago |
| Sep 25, 2026 | Peter McNamara Chief Scientific Officer | FTax withholding Common Stock10b5-1 | -444 | $23.67 | $11k | 54,841 | 11 d ago |
| Sep 30, 2026 | Peter McNamara Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -536 | $23.04 | $12k | 54,305 | 11 d ago |
| Sep 3, 2026 | Alise Reicin Chief Executive Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +69,250 | $0.00 | $0 | 69,250 | 35 d ago |
| Sep 3, 2026 | Peter McNamara Chief Scientific Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +21,000 | $0.00 | $0 | 21,000 | 35 d ago |
| Sep 3, 2026 | Marcella K. Ruddy Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +24,250 | $0.00 | $0 | 24,250 | 35 d ago |
| Sep 3, 2026 | Marc Schwabish Chief Business Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +17,750 | $0.00 | $0 | 17,750 | 35 d ago |
| Sep 3, 2026 | Daniel Lochner Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +24,250 | $0.00 | $0 | 24,250 | 35 d ago |
| Aug 25, 2026 | Peter McNamara Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +43 | $14.71 | $633 | 55,328 | Aug 26, 2026 |
| Aug 25, 2026 | Peter McNamara Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -43 | $36.52 | $1,570 | 55,285 | Aug 26, 2026 |
| Aug 25, 2026 | Peter McNamara Chief Scientific Officer | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -43 | $0.00 | $0 | 7,787 | Aug 26, 2026 |
| Aug 12, 2026 | Peter McNamara Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +43 | $14.71 | $633 | 55,328 | Aug 14, 2026 |
| Aug 12, 2026 | Peter McNamara Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -43 | $35.00 | $1,505 | 55,285 | Aug 14, 2026 |
| Aug 12, 2026 | Peter McNamara Chief Scientific Officer | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -43 | $0.00 | $0 | 7,830 | Aug 14, 2026 |
| Jun 30, 2026 | Peter McNamara Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +172 | $14.71 | $2,530 | 55,457 | Jul 1, 2026 |
| Jun 30, 2026 | Peter McNamara Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -172 | $35.00 | $6,020 | 55,285 | Jul 1, 2026 |
| Jun 30, 2026 | Peter McNamara Chief Scientific Officer | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -172 | $0.00 | $0 | 7,873 | Jul 1, 2026 |
| Jun 20, 2026 | Alise Reicin Chief Executive Officer | FTax withholding Common Stock | -924 | $30.34 | $28k | 310,623 | Jun 23, 2026 |
| Jun 11, 2026 | Daniel Lochner Chief Financial Officer | AGrant or award Performance Stock Option (Right to Buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Jun 12, 2026 |
| Jun 9, 2026 | Phillip B. Donenberg director | AGrant or award Stock Option (Right to Buy)derivative | +10,200 | $0.00 | $0 | 10,200 | Jun 10, 2026 |
| Jun 9, 2026 | Timothy A Springer director, owner | AGrant or award Stock Option (Right to Buy)derivative | +10,200 | $0.00 | $0 | 10,200 | Jun 10, 2026 |
| Jun 9, 2026 | Praveen P. Tipirneni director | AGrant or award Stock Option (Right to Buy)derivative | +10,200 | $0.00 | $0 | 10,200 | Jun 10, 2026 |
| Jun 9, 2026 | Stefan Vitorovic director | AGrant or award Stock Option (Right to Buy)derivative | +10,200 | $0.00 | $0 | 10,200 | Jun 10, 2026 |
| Jun 8, 2026 | Jessica Caroline Chutter director | AGrant or award Stock Option (Right to Buy)derivative | +20,400 | $0.00 | $0 | 20,400 | Jun 10, 2026 |
| May 4, 2026 | Marcella K. Ruddy Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -1,065 | $30.00 | $32k | 67,682 | May 6, 2026 |
| Apr 1, 2026 | Francois Nader director | AGrant or award Stock Option (Right to Buy)derivative | +20,400 | $0.00 | $0 | 20,400 | Apr 3, 2026 |
| Apr 1, 2026 | Marcella K. Ruddy Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -1,000 | $31.05 | $31k | 68,747 | Apr 3, 2026 |
| Mar 6, 2026 | Marcella K. Ruddy Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $30.00 | $300k | 69,747 | Mar 9, 2026 |
| Mar 6, 2026 | Peter McNamara Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +2,500 | $2.38 | $5,950 | 61,332 | Mar 9, 2026 |
| Mar 6, 2026 | Peter McNamara Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +215 | $14.71 | $3,163 | 61,547 | Mar 9, 2026 |
| Mar 6, 2026 | Peter McNamara Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -6,047 | $30.00 | $181k | 55,500 | Mar 9, 2026 |
| Mar 6, 2026 | Peter McNamara Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -215 | $35.00 | $7,525 | 55,285 | Mar 9, 2026 |
| Mar 6, 2026 | Peter McNamara Chief Scientific Officer | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -2,500 | - | - | 31,959 | Mar 9, 2026 |
| Mar 6, 2026 | Peter McNamara Chief Scientific Officer | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -215 | $0.00 | $0 | 8,045 | Mar 9, 2026 |
| Mar 4, 2026 | Daniel Lochner Chief Financial Officer | AGrant or award Common Stock | +26,500 | $0.00 | $0 | 58,544 | Mar 5, 2026 |
| Mar 4, 2026 | Alise Reicin Chief Executive Officer | AGrant or award Common Stock | +76,500 | $0.00 | $0 | 311,547 | Mar 5, 2026 |
| Mar 4, 2026 | Marcella K. Ruddy Chief Medical Officer | AGrant or award Common Stock | +26,500 | $0.00 | $0 | 79,747 | Mar 5, 2026 |
| Mar 4, 2026 | Marc Schwabish Chief Business Officer | AGrant or award Common Stock | +19,500 | $0.00 | $0 | 45,314 | Mar 5, 2026 |
| Feb 11, 2026 | Alise Reicin Chief Executive Officer | POpen-market purchase Common Stockindirect: By Trust | +2,500 | $21.10 | $53k | 127,030 | Mar 5, 2026 |
| Mar 3, 2026 | Peter McNamara Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -1,649 | $22.06 | $36k | 37,482 | Mar 5, 2026 |
| Mar 4, 2026 | Daniel Lochner Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +24,250 | $0.00 | $0 | 24,250 | Mar 5, 2026 |
| Mar 4, 2026 | Peter McNamara Chief Scientific Officer | AGrant or award Common Stock10b5-1 | +23,000 | $0.00 | $0 | 60,482 | Mar 5, 2026 |
| Mar 4, 2026 | Marcella K. Ruddy Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +24,250 | $0.00 | $0 | 24,250 | Mar 5, 2026 |
| Mar 4, 2026 | Marc Schwabish Chief Business Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +17,750 | $0.00 | $0 | 17,750 | Mar 5, 2026 |
| Mar 4, 2026 | Peter McNamara Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -1,650 | $25.00 | $41k | 58,832 | Mar 5, 2026 |
| Mar 4, 2026 | Alise Reicin Chief Executive Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +69,250 | $0.00 | $0 | 69,250 | Mar 5, 2026 |
| Mar 4, 2026 | Peter McNamara Chief Scientific Officer | AGrant or award Employee Stock Option (Right to Buy)derivative10b5-1 | +21,000 | $0.00 | $0 | 21,000 | Mar 5, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Jessica Caroline Chutterdirector
- Phillip B. Donenbergdirector
- Daniel LochnerChief Financial Officer
- Terrance McGuiredirector
- Peter McNamaraChief Scientific Officer
- Francois Naderdirector
- Alise ReicinChief Executive Officer
- Marcella K. RuddyChief Medical Officer
- Timothy A Springerdirector, owner
- Marc SchwabishChief Business Officer
- Praveen P. Tipirnenidirector
- Stefan Vitorovicdirector
Questions about TECX
Answered from the filings on this page, as of the latest one.
Are insiders buying TECX?
As of Oct 2, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 3 open-market sells worth $15k by 1 insider at Tectonic Therapeutic, Inc. in the last 90 days, net -$15k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade TECX on the open market?
Peter McNamara (Chief Scientific Officer) sold $12k of TECX on Sep 30, 2026 and filed the Form 4 on Oct 2, 2026. InsiderTell scored 0 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at Tectonic Therapeutic, Inc.?
12 people have filed a Form 4 at Tectonic Therapeutic, Inc., among them Jessica Caroline Chutter (director), Phillip B. Donenberg (director), Daniel Lochner (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.